RT Journal Article
SR Electronic
T1 Metabolomics strategy for diagnosing urinary tract infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.07.21255028
DO 10.1101/2021.04.07.21255028
A1 Gregson, Daniel B.
A1 Wildman, Spencer D.
A1 Chan, Carly C.Y.
A1 Bihan, Dominique G.
A1 Groves, Ryan A.
A1 Aburashed, Raied
A1 Rydzak, Thomas
A1 Pittman, Keir
A1 Van Bavel, Nicolas
A1 Lewis, Ian A.
YR 2024
UL http://medrxiv.org/content/early/2024/09/05/2021.04.07.21255028.abstract
AB Metabolomics has emerged as a mainstream approach for investigating complex metabolic phenotypes but has yet to be integrated into routine clinical diagnostics. Metabolomics-based diagnosis of urinary tract infections (UTIs) is a logical application of this technology since microbial waste products are concentrated in the bladder and thus could be suitable markers of infection. We conducted an untargeted metabolomics screen of clinical specimens from patients with suspected UTIs and identified two metabolites, agmatine and N6-methyladenine, that are predictive of culture positive samples. We developed a 3.2-minute LC-MS assay to quantify these metabolites and showed that agmatine and N6-methyladenine correctly identify UTIs caused by 13 Enterobacterales species and 3 non-Enterobacterales species, accounting for over 90% of infections (agmatine AUC > 0.95; N6-methyladenine AUC > 0.89). These markers were robust predictors across two blinded cohorts totaling 1,629 patient samples. These findings demonstrate the potential utility of metabolomics in clinical diagnostics for rapidly detecting UTIs.Competing Interest StatementDrs. Lewis, Gregson and Mr. Groves are authors on a patent relating to the use of LC-MS for detecting urinary tract infections. No other competing interests declared.Funding StatementThis work was supported by Genome Canada (10019200), the Canadian Institute of Health Research (162790), the University of Calgary (Biomedical Engineering 10011121), and Alberta Precision Laboratories. I.A.L is supported by an Alberta Innovates Translational Health Chair. T.R. is supported by an Eyes-High Postdoctoral Fellowship from the University of Calgary. S.D.W. was supported in part by an NSERC Undergraduate Summer Research Award. Metabolomics data were acquired at the Calgary Metabolomics Research Facility, which is supported by the International Microbiome Centre and the Canada Foundation for Innovation (CFI-JELF 34986).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Calgary's Conjoint Health Research Ethics Board, under certificate # REB16-0167I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials. Raw mass spectrometry data are available from the study team upon request.